Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets

David M Spiegel, Kate Brady, David M Spiegel, Kate Brady

Abstract

Calcium balance in chronic kidney disease is poorly understood as calcium deficiency is a stimulus for secondary hyperparathyroidism and consequent bone loss while calcium excess promotes extraosseous calcifications. To help resolve this, we evaluated calcium balance in normal individuals and in patients with chronic kidney disease (CKD) on daily diets containing 800 and 2000 mg elemental calcium. Both normal individuals and patients with late stage 3 and stage 4 CKD were in slightly negative to neutral calcium balance on the 800-mg calcium diet. Normal individuals were in modest positive calcium balance on the 2000-mg diet, while patients with CKD on the same diet were in marked positive calcium balance at least over the 9 days of study; and significantly greater than the normal individuals. Increased calcium intake significantly decreased 1,25-dihydroxy-vitamin D and intact parathyroid hormone levels but did not alter the serum calcium concentration. Thus, our findings have important implications for both preventing calcium deficiency and loading in individuals with late stage 3 and stage 4 CKD.

Trial registration: ClinicalTrials.gov NCT00974532.

Figures

Figure 1
Figure 1
Timeline of study interventions
Figure 2
Figure 2
Serum calcium (a) and phosphorus (b) on 800 and 2000 mg calcium diets. filled circles = CKD subjects; filled triangles = controls
Figure 3
Figure 3
Serum 1,25 dihydroxy-vitamin D (a) and iPTH (b) on 800 and 2000 mg calcium diets. filled circles = CKD subjects; filled triangles = controls
Figure 4
Figure 4
24-hour urinary phosphorus excretion (a) and tubular reabsorption of phosphorus (b) filled circles = CKD subjects; filled triangles = controls.
Figure 5
Figure 5
24-hour urinary calcium excretion (a) and stool calcium/phosphorus ratio (b).
Figure 6
Figure 6
Estimated calcium balance in controls and CKD subjects. filled circles = CKD subjects; filled triangles = controls

References

    1. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2006;71:31–38.
    1. Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5: Achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22:1171–1176.
    1. Coburn JW, Koppel MH, Brickman AS, et al. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int. 1973;3:264–272.
    1. Perez AV, Picotto G, Carpentieri AR, et al. Minireview on regulation of intestinal calcium absorption. Digestion. 2008;77:22–34.
    1. Hunt CD, Johnson LK. Calcium requirements: new estimations for men and women by cross-sectional statistical analysis of calcium balance data from metatolic studies. Am J Clin Nutr. 2007;86:1054–1063.
    1. Wilz DR, Gray RW, Dominguez JH, et al. Plasma 1,25-(OH)2-vitamin D concentrations and net intestinal calcium, phosphate, and magnesium absorption in humans. Am J Clin Nutr. 1979;32:2052–2060.
    1. Smothers RL, Levine BS, Singer FR. Relationship between urinary calcium and calcium intake during calcitriol administration. Kidney Int. 1986;29:578–583. eta al.
    1. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney diseases stages 3 and 4. Am J Kidney Dis. 2004;43:877–890.
    1. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsules for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–276.
    1. Oliverira RB, Cancela ALE, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–291.
    1. Sigrist MK, Taal MW, Bungay P, et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:1241–1248.
    1. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75:890–897.
    1. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697–703.
    1. Kovesdy CP, Kuchmak O, Lu JL, et al. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis. 2010;56:842–851.
    1. Slatopolsky E, Robson AM, Elkan I, et al. Control of phosphate excretion in uremic man. J Clin Invest. 1968;47:1865–1874.
    1. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol. 2010;5(Suppl 1):S12–S22.
    1. Phang JM, Berman M, Finerman GA, et al. Dietary perturbation of calcium metabolism in normal man: compartmental analysis. J Clin Invest. 1969;48:67–77.
    1. Shroff RC, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748–1757.
    1. Coburn JW, Brickman AS, Hartenbower DL, et al. Intestinal phosphate absorption in normal and uremic man: effects of 1,25(OH)2-vitamin D3 and 1alpha(OH)-vitamin D3. Adv Exp Med Biol. 1977;81:549–557.
    1. Dawson-Hughes B, Stern DT, Shipp CC, et al. Effect of lowering dietary calcium intake on fractional whole body calcium retention. J Clin Endocrinol Metab. 1988;67:62–68.
    1. IOM (Institute of Medicine) Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press; Washington, DC: 2011.
    1. Chu JY, Margen S, Calloway DH, et al. Integumentary loss of calcium. Am J Clin Nutr. 1979;32:1699–1702.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner